Sign inJoin waitlistJoin the waitlist

Brittani Seynnaeve

Associate Fellowship Program Director, Division of Hematology-Oncology · Univ of Pittsburgh Sch of Med

Credentials: · · ·

History

Division of Hematology-Oncology · Univ of Pittsburgh Sch of Med
Present
Clinical Oncology Research · UPMC Medical Education
Present
Univ of Pittsburgh Sch of Med
Present

Pediatric Hematology Oncology
Clinical Research, University of Pittsburgh
2014–2017
University of Pittsburgh Cancer Institute
2015–2017
Pediatrics
Clinical Research, University of Pittsburgh
2011–2014
Clinical Research, University of Pittsburgh
West Virginia University School of Medicine
2007–2011
University of Pittsburgh, graduating
2003–2007

Research

Adolescent and young adult oncology-past, present, and future
Current Anthropology · 2019 · 208 citations
Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma
Scientific Reports · 2017 · First of 7 authors · 49 citations
Expression and characterization of mutations in human very long-chain acyl-CoA dehydrogenase using a prokaryotic system
Molecular Genetics and Metabolism · 2007 · 40 citations

John Kirkwood
5 papers
Michael Sargen
5 papers
Alberto Pappo
4 papers
EC
Emily Christison-Lagay
4 papers
SM
Sarah Mitchell
4 papers
Theodore Laetsch
4 papers
Alexander Davit
3 papers
Arivarasan Karunamurthy
3 papers
Armita Bahrami
3 papers
Marcus Malek
3 papers
Robyn Gartrell
3 papers
Allison Close
2 papers · 1 as a fellow

Clinical trials

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
Principal investigator · Recruiting
Children's Oncology Group
2027–2028
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2026–2029
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029